Leuprolide
An FDA-approved GnRH agonist used for prostate cancer, endometriosis, and precocious puberty through hormonal suppression.
What is Leuprolide?
Leuprolide is a synthetic nonapeptide GnRH agonist that, when given continuously, paradoxically suppresses the reproductive hormone axis. After an initial stimulatory phase ('flare'), continuous administration downregulates GnRH receptors, dramatically reducing testosterone and estrogen levels. It is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
What Leuprolide Is Investigated For
Leuprolide is one of the most clinically established peptide therapeutics anywhere — FDA-approved since 1985 and in continuous large-scale clinical use for advanced prostate cancer (androgen deprivation therapy), endometriosis, uterine fibroids (preoperative), and central precocious puberty, with additional widespread off-label use in IVF pituitary suppression protocols. The strongest evidence is in prostate cancer: the LEADER-predecessor program and decades of post-marketing data demonstrate medical castration within 3–4 weeks and improved outcomes in combination with radiation or second-generation anti-androgens (EMBARK, NRG/RTOG 9408). Endometriosis pain reduction and precocious puberty suppression both have strong trial support. The key clinical caveats are not about efficacy but about managing the known consequences of profound hormone suppression: the initial testosterone 'flare' in prostate cancer (requiring anti-androgen pre-loading), substantial bone mineral density loss with extended use (warranting DXA and bisphosphonate/denosumab consideration), and cardiovascular risk signals that have driven interest in GnRH antagonists (degarelix, relugolix) in some high-risk patients. This is a legitimately well-studied drug — not a wellness peptide — and any use should be physician-directed for a specific FDA-approved indication.
History & Discovery
The synthesis of native gonadotropin-releasing hormone (GnRH, originally LHRH) by Andrew Schally and Roger Guillemin in the early 1970s — work that earned the 1977 Nobel Prize in Physiology or Medicine — opened the door to the GnRH agonist class. The therapeutic insight that subsequently transformed prostate cancer care emerged from a paradox: continuous GnRH receptor stimulation, contrary to the pulsatile native pattern, causes desensitization and downregulation of pituitary gonadotropes, producing profound LH/FSH suppression and consequent gonadal hormone shutdown. Andrzej Schally's group at Tulane and others identified the structural modifications that enhanced potency and metabolic stability — particularly D-amino acid substitution at position 6 and ethylamide substitution at position 10. Leuprolide (D-Leu6, des-Gly10, Pro-NHEt-GnRH) was developed by Abbott Laboratories (now AbbVie under the TAP/Takeda partnership history) and received FDA approval in April 1985 as Lupron Depot for advanced prostate cancer — replacing surgical orchiectomy as the primary form of androgen-deprivation therapy and rapidly becoming the standard of care. Approval expanded to endometriosis (1990), uterine fibroids (1995), and central precocious puberty (1993). The depot formulations — initially monthly, then 3-month (1995), 4-month, and 6-month (2011) — used PLGA microsphere or polymer-implant technology to enable sustained release and dramatically improved adherence compared with daily injection. Lupron became one of the most commercially successful endocrinology products in history and a foundational drug across urologic oncology, gynecology, pediatric endocrinology, and reproductive medicine. Subsequent GnRH agonists (goserelin, triptorelin, histrelin) and the later GnRH antagonist class (degarelix injectable, relugolix oral) compete in the same therapeutic space. Long-term safety surveillance has identified bone-density loss, cardiovascular risk, and metabolic effects of chronic androgen deprivation as the principal concerns shaping contemporary management — leading to expanded use of bone-protective adjuncts and cardiovascular risk discussion as part of standard ADT planning.
How It Works
Leuprolide overwhelms the brain's reproductive hormone system. By constantly stimulating the GnRH receptor (instead of the normal pulsing pattern), it causes the receptor to shut down, which stops testosterone and estrogen production — useful for hormone-sensitive cancers and conditions.
Leuprolide is a GnRH superagonist (D-Leu6, des-Gly10, Pro-NHEt) with 80x greater potency than native GnRH. Initial administration causes a 'flare' with increased LH, FSH, and sex steroids. Continuous exposure causes GnRH receptor internalization and downregulation, uncoupling from Gq signaling. This results in medical castration levels of testosterone (<50 ng/dL) or estrogen within 2-4 weeks. Depot formulations use microsphere or polymer technology for 1-6 month sustained release.
Evidence Snapshot
Human Clinical Evidence
Extensive. One of the most widely used hormonal therapies with decades of clinical data across multiple indications.
Animal / Preclinical
Comprehensive. GnRH receptor desensitization is thoroughly characterized.
Mechanistic Rationale
Very strong. GnRH receptor pharmacology and HPG axis regulation are well-understood.
Research Gaps & Open Questions
What the current literature has not yet settled about Leuprolide:
- 01GnRH agonist vs. GnRH antagonist comparative cardiovascular outcomes — the PRONOUNCE trial (degarelix vs. leuprolide) was inconclusive on cardiovascular endpoints; the optimal selection of agonist vs. antagonist in patients with pre-existing cardiovascular disease remains debated.
- 02Optimal duration of adjuvant ADT with definitive radiation in localized prostate cancer — high-risk disease typically receives 24–36 months but optimal duration in intermediate-risk disease and the role of intensification with second-generation anti-androgens (apalutamide, enzalutamide) is evolving.
- 03Bone health management protocols during extended ADT — bisphosphonate, denosumab, and selective estrogen receptor modulator approaches are all used; comparative effectiveness and patient-selection algorithms are imperfect.
- 04Intermittent vs. continuous ADT — multiple large trials suggest intermittent ADT is non-inferior for some endpoints with quality-of-life benefit, but practice patterns and patient-selection criteria remain inconsistent.
- 05Endometriosis treatment durations beyond 12 months — labeled limit is 12 months with add-back; longer-duration use is sometimes clinically necessary but lacks strong trial support.
- 06Cognitive and mood effects of long-term ADT — recognized signal for fatigue, cognitive complaints, and depression risk during ADT, but biological mechanisms and effective interventions are incompletely characterized.
Forms & Administration
SC or IM injection. Available as daily injection (1mg), monthly depot (7.5mg), 3-month depot (22.5mg), 4-month depot (30mg), or 6-month depot (45mg). All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Prostate cancer (advanced): 7.5 mg monthly depot, 22.5 mg 3-month depot, 30 mg 4-month depot, or 45 mg 6-month depot, IM or SC depending on formulation. Eligard (SC polymer-implant formulation) at the same dose strengths is widely used. Endometriosis: 3.75 mg monthly depot for up to 6 months (12 months with norethindrone add-back); 11.25 mg 3-month depot is also used. Uterine fibroids: 3.75 mg monthly depot for up to 3 months as preoperative therapy. Central precocious puberty: 7.5–15 mg monthly depot or 11.25–30 mg 3-month depot, weight- and response-titrated.
Frequency
Depot injection at the labeled interval (monthly, 3-month, 4-month, or 6-month). The pediatric histrelin implant (Supprelin LA) provides 12-month sustained release as an alternative for precocious puberty. Daily SC formulation (1 mg) exists for IVF protocol use but is uncommon in routine practice.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Prostate cancer ADT is typically chronic indefinite for metastatic disease, time-limited (6 months to several years) when used as adjuvant to definitive radiation in localized high-risk disease, or intermittent in selected biochemical-recurrence patients. Endometriosis treatment is FDA-labeled for up to 6 months without add-back and up to 12 months with hormonal add-back to mitigate bone loss. Central precocious puberty treatment continues until appropriate physiologic age for puberty (typically discontinued by ages 11–12 in girls and 12–13 in boys).
Protocol Notes
The initial testosterone or estrogen 'flare' during the first 1–2 weeks of GnRH agonist therapy is the classical and clinically important pharmacology to manage. In prostate cancer, the flare can transiently worsen bone-metastasis pain, ureteral obstruction, or spinal cord compression risk in patients with high tumor burden — anti-androgen pre-loading and concurrent therapy (bicalutamide, flutamide) is standard practice for the first 2–4 weeks. In endometriosis and fibroids, the flare can transiently worsen pain symptoms. Bone mineral density loss is the most clinically significant chronic complication of long-term ADT and merits proactive management: baseline DXA, calcium and vitamin D supplementation, weight-bearing exercise counseling, and consideration of bisphosphonate or denosumab therapy in patients on extended ADT. Cardiovascular risk — particularly in patients with pre-existing cardiac disease — is a recognized association and shapes the shift toward GnRH antagonists (degarelix, relugolix) in some high-risk populations where the cardiovascular signal appears smaller in head-to-head data (HERO trial, PRONOUNCE trial). For endometriosis and uterine fibroid management, hormonal add-back therapy (norethindrone acetate 5 mg daily, or low-dose estrogen plus progestin combinations) is used to mitigate the menopausal-symptom burden and bone-loss risk during extended treatment. Hot flashes, vaginal dryness, mood changes, and decreased libido are predictable and should be discussed in advance. For central precocious puberty, regular monitoring of stimulated LH levels and bone age progression guides dose and continuation decisions. The therapy is reversible — gonadal function returns within months after discontinuation, allowing physiologically appropriate puberty.
Leuprolide is FDA-approved for several specific indications across oncology, gynecology, and pediatric endocrinology. It should be prescribed by a clinician familiar with the relevant indication and the management of androgen or estrogen deprivation. Use outside approved indications (notably IVF protocols, where it is widely used off-label) requires specialist supervision.
Timeline of Effects
Onset
After first depot injection, an initial 'flare' of LH/FSH and consequent rise in testosterone or estrogen occurs over the first 7–14 days. Pituitary desensitization develops over the next 2–4 weeks. Castrate-level testosterone (<50 ng/dL, or by current consensus <20 ng/dL for optimal oncologic outcome) is achieved in most prostate cancer patients by week 3–4. Estrogen suppression in premenopausal women on endometriosis or fibroid indications follows a similar timeline. Symptom benefit (carcinoid flushing analog isn't applicable here, but bone-pain or endometriosis-pain reduction) is typically observed by 4–8 weeks.
Peak Effect
Maximal hormonal suppression is sustained throughout the depot interval with appropriate redosing. PSA decline in advanced prostate cancer typically continues through months 1–6 to a nadir level that is prognostic of long-term outcome. BMD loss begins within months of continuous ADT and is progressive without intervention. Hot flash and other symptom intensity is maximal during the first months of therapy and partially attenuates over time for most patients.
After Discontinuation
Pituitary recovery and gonadal function return after discontinuation of GnRH agonist therapy is typically slow — testosterone recovery to baseline can take 6–12 months or longer, particularly after extended (multi-year) ADT and in older men. Some patients (particularly older men) never fully recover baseline testosterone. In premenopausal women, menstrual cycles typically resume within 1–6 months after stopping, with fertility restoration following. The depot pharmacokinetics mean a single injection's effect persists for the entire labeled interval — there is no rapid 'wash-out' option short of switching to a GnRH antagonist (which produces faster reversal but doesn't accelerate recovery from prior agonist exposure).
Common Questions
Who Leuprolide Is NOT For
- •Pregnancy — leuprolide can cause fetal harm; effective contraception is required for women of reproductive potential during therapy and for a period after discontinuation.
- •Breastfeeding — not recommended.
- •Known hypersensitivity to leuprolide or to GnRH or GnRH analogs (cross-reactivity is possible).
- •Undiagnosed abnormal vaginal bleeding — should be evaluated before initiating gynecologic indication therapy.
- •Severe spinal cord compression or urinary tract obstruction in advanced prostate cancer — the testosterone flare can acutely worsen these conditions. Anti-androgen pre-loading is mandatory; in some cases GnRH antagonist (degarelix) is preferred to avoid the flare entirely.
- •Pre-existing severe osteoporosis without bone-protective co-therapy — relative contraindication; bone protection (bisphosphonate, denosumab) should accompany extended GnRH agonist therapy in at-risk patients.
- •Significant pre-existing cardiovascular disease — relative contraindication warranting consideration of GnRH antagonist as an alternative; the PRONOUNCE and HERO trials inform this decision-making.
- •QT interval prolongation or risk factors for torsades de pointes — leuprolide can prolong QT; ECG and electrolyte monitoring is appropriate in at-risk patients.
Drug & Supplement Interactions
Leuprolide has a relatively limited classical drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. The clinically important interactions are largely pharmacodynamic. Anti-androgens (bicalutamide, flutamide, nilutamide, enzalutamide): co-administration is standard practice during the testosterone flare period and as continued combined androgen blockade. The combination is intended and not a problematic interaction; recent trials (EMBARK with enzalutamide) define expanded combined-blockade indications. QT-prolonging medications: leuprolide can prolong QT interval, and combination with other QT-prolonging agents (Class IA and III antiarrhythmics, certain antiemetics, fluoroquinolones, methadone) warrants ECG monitoring and electrolyte management. Diabetic medications: long-term ADT alters insulin sensitivity and increases diabetes risk; patients on insulin or oral antihyperglycemics may need dose adjustment over months of therapy. Glycemic monitoring is part of routine ADT follow-up. Antihypertensives and cardiac medications: ADT affects lipid profiles and cardiovascular physiology; medication adjustments may be needed over time. Warfarin: minimal documented direct interaction, but overall metabolic shifts during ADT can affect anticoagulation control; INR monitoring should continue as usual with attention during the initiation period. Corticosteroids: commonly used together in prostate cancer for symptom management; the combination is intended and generally well-tolerated. As with any chronic specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber.
Safety Profile
Common Side Effects
Cautions
- • Initial testosterone flare can worsen prostate cancer symptoms
- • Long-term use causes bone density loss
- • Cardiovascular risk with prolonged androgen deprivation
- • Not for use in pregnancy
What We Don't Know
Well-characterized safety profile with decades of clinical use. Long-term bone and cardiovascular effects are monitored.
Legal Status
United States
Leuprolide (Lupron, Lupron Depot, Eligard, multiple generics) is FDA-approved (initial approval April 1985) for advanced prostate cancer, endometriosis, uterine fibroids (preoperative), and central precocious puberty. Multiple branded and generic depot formulations across 1-, 3-, 4-, and 6-month intervals are widely available through specialty pharmacy distribution. It is a prescription-only specialty medication, not a controlled substance. Cost is high for branded depot formulations; generic options have moderated pricing.
International
Approved across major markets globally (EMA, MHRA, Health Canada, TGA, Japan, China) for similar indications. Multiple generic depot formulations are available worldwide. Goserelin (Zoladex), triptorelin (Decapeptyl), and histrelin (Vantas) are common alternatives in international markets. The newer oral GnRH antagonist relugolix (Orgovyx) has expanded the class beyond injection.
Sports & Competition
Leuprolide and other GnRH agonists are listed on the WADA Prohibited List under S4 (Hormone and Metabolic Modulators), specifically section S4.3 (Agents Modifying Myostatin Function — historically) and section S4.5 (Hormone and Metabolic Modulators) for any use in male athletes. The classification reflects use in 'post-cycle therapy' contexts following anabolic-androgenic steroid administration, where GnRH agonists are sometimes used in attempts to restart endogenous testosterone production. Therapeutic use for prostate cancer or other approved indications under appropriate Therapeutic Use Exemption is permitted; non-therapeutic use is prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Leuprolide is a testosterone-boosting drug because it stimulates the GnRH receptor.
Reality
It is a profound testosterone-lowering drug in chronic use. The initial 1–2 week stimulatory 'flare' is followed by GnRH receptor desensitization and downregulation, producing castrate-level testosterone within 3–4 weeks. The pharmacology depends on continuous (not pulsatile) exposure — depot formulations exist precisely to maintain the suppressive desensitization. Anyone using it expecting testosterone elevation is using it incorrectly.
Myth
GnRH agonists like leuprolide can be safely used short-term to 'restart' testosterone after anabolic steroid use.
Reality
This is a wellness-clinic and bodybuilding-forum claim, not clinical practice. Single-dose or short-course GnRH agonist use to trigger a transient LH/FSH surge has no controlled-trial evidence base, and even short-course exposure can produce prolonged HPG-axis suppression rather than the intended 'restart.' Triptorelin in PCT contexts has the same caveats. This off-label use is not supported by data and carries risk of unintended chronic suppression.
Myth
Leuprolide is permanent — once you start, you can't recover normal hormone function.
Reality
GnRH agonist effects are reversible in the majority of patients. Testosterone and estrogen levels recover after discontinuation, though recovery can be slow (6–12 months or longer) and is incomplete in some older men after extended ADT. In premenopausal women treated for endometriosis or fibroids, menstrual cycles typically resume within 1–6 months. In central precocious puberty, normal pubertal progression resumes after discontinuation.
Myth
All GnRH agonists are interchangeable for any indication.
Reality
Leuprolide, goserelin, triptorelin, histrelin, and others share the GnRH agonist class mechanism but differ in formulation options, dosing intervals, depot delivery technology, regulatory approval scope, and price. Switching between agents for prostate cancer ADT is generally feasible but should be done with attention to formulation-specific PK profiles. Indication-specific approval matters: not every product is approved for every condition.
Myth
Bone loss on leuprolide is a minor concern that doesn't need active management.
Reality
ADT-induced bone loss is substantial, predictable, and clinically important — fracture risk increases meaningfully with extended ADT. Baseline DXA, calcium and vitamin D supplementation, lifestyle counseling, and consideration of bisphosphonate or denosumab therapy are part of the standard of care for extended ADT, not optional adjuncts.
Published Research
33 studiesEnzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis
GnRH analogues and dienogest for second line treatment of endometriosis-associated pain: a systematic review, meta-analysis, and network meta-analysis
The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis
Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
Comparison of the effects of two different trigger strategies - dual (hCG + Leuprolide) versus hCG trigger - in antagonist non-donor IVF: a randomized controlled trial
Efficacy and safety of different subsequent therapies after fertility preserving surgery for endometriosis: A systematic review and network meta-analysis
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer
Evaluation of safety and effectiveness of gestrinone in the treatment of endometriosis: a systematic review and meta-analysis
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone
Testicular vs adrenal sources of hydroxy-androgens in prostate cancer
Neoadjuvant Enzalutamide Prior to Prostatectomy
Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer
Efficacy of nafarelin in assisted reproductive technology: a meta-analysis
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis
Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate
Quick Facts
- Class
- GnRH Agonist
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 33PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.